Identifying factors that impact survival among women with inflammatory breast cancer

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 870-875

  Dawood, S ^a,b   Ueno, N T ^a   Valero, V ^a   Woodward, W A ^a   Buchholz, T A ^b   Hortobagyi, G N ^a   Gonzalez angulo, A M ^a   Cristofanilli, M ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUBAI HOSPITAL   (United Arab Emirates)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Inflammatory breast cancer; Stage III IV; Subgroups

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INFLAMMATORY BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; WOMEN'S HEALTH;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84859508293     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr319     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277-300.
2. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 1985; 74: 291-297.
3. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999; 8: 1117-1121.
4. Wingo PA, Jamison PM, Young JL, Gargiullo P. Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 2004; 15(3): 321-328.
5. Ueno NT, Buzdar AU, Singletary SE et al. Combined modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Center. Cancer Chemother Pharmacol 1997; 40(4): 321-329.
6. Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005; 65(6): 2170-2178.
7. Van Laere SJ, Van den Eynden GG, Van der Auwera I et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006; 95(3): 243-255.
8. Van Laere S, Van der Auwera I, Van den Eynden G et al. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer 2007; 97(8): 1165-1174.
9. Bie' che I, Lerebours F, Tozlu S et al. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004; 10(20): 6789-6795.
10. Nguyen DM, Sam K, Tsimelzon A et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 2006; 12(17): 5047-5054.
11. Van Laere S, Beissbarth T, Van der Auwera I et al. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer. Clin Cancer Res 2008; 14(22): 7452-7460.
12. Kim T, Lau J, Erban J. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer 2006; 5(5): 386-395.
13. Green FL, Page DL, Fleming ID et al. AAJCC Cancer Staging Manual, 6th edition. New York: Springer-Verlag 2002; 225-281.
14. Iwamoto T, Bianchini G, Qi Y et al. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 2011; 125(3): 785-795.
15. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
16. Van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
17. Sutherland S, Ashley S, Walsh G et al. Inflammatory breast cancer-The Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007. Cancer 2010; 116 (11 Suppl): 2815-2820.
18. Zell JA, Tsang WY, Taylor TH et al. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 2009; 11(1): R9.
19. Dawood S, Broglio K, Gong Y et al. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 2008; 112(9): 1905-1911.
20. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375(9712): 377-384.
21. Rapiti E, Verkooijen HM, Vlastos G et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006; 24(18): 2743-2749.
22. Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2008; 247(5): 732-738.
23. Rao R, Feng L, Kuerer HM et al. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 2008; 15(6): 1696-1702.
24. Carmichael AR, Anderson ED, Chetty U, Dixon JM. Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol 2003; 29(1): 17-19.
25. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002; 132(4): 620-626.
26. Khan SA. Does resection of an intact breast primary improve survival in metastatic breast cancer? Oncology 2007; 21(8): 924-931.